Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2011-05-17
2011-05-17
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S228200, C514S235200, C514S253010, C514S278000, C514S312000, C546S019000, C546S153000, C546S159000, C546S160000, C546S171000, C544S058600, C544S128000, C544S328000, C544S331000, C544S363000
Reissue Patent
active
RE042376
ABSTRACT:
This invention provides compounds of formula I having the structurewherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
REFERENCES:
patent: 5480883 (1996-01-01), Spada et al.
patent: 5686457 (1997-11-01), Traxler et al.
patent: 6002008 (1999-12-01), Wissner et al.
patent: 6288082 (2001-09-01), Wissner et al.
patent: 6972288 (2005-12-01), Himmelsbach et al.
patent: 0520722 (1992-12-01), None
patent: 0566226 (1993-10-01), None
patent: 0602851 (1994-06-01), None
patent: 0635498 (1995-01-01), None
patent: 0635507 (1995-01-01), None
patent: 9515758 (1995-06-01), None
patent: WO 95/15758 (1995-06-01), None
patent: 9519774 (1995-07-01), None
patent: 9519970 (1995-07-01), None
patent: WO 95/19774 (1995-07-01), None
patent: WO 95/19970 (1995-07-01), None
patent: 9521613 (1995-08-01), None
patent: 9523141 (1995-08-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 95/23141 (1995-08-01), None
patent: 9524190 (1995-09-01), None
patent: WO 95/24190 (1995-09-01), None
patent: 9609294 (1996-03-01), None
patent: WO 96/09294 (1996-03-01), None
patent: 9633977 (1996-10-01), None
patent: 9633978 (1996-10-01), None
patent: 9633979 (1996-10-01), None
patent: 9633980 (1996-10-01), None
patent: 9633981 (1996-10-01), None
patent: WO 96/33977 (1996-10-01), None
patent: WO 96/33978 (1996-10-01), None
patent: WO 96/33979 (1996-10-01), None
patent: WO 96/33980 (1996-10-01), None
patent: WO 96/33981 (1996-10-01), None
patent: 9802434 (1998-01-01), None
patent: 9802438 (1998-01-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: 9813350 (1998-04-01), None
patent: WO 98/13350 (1998-04-01), None
patent: 9843960 (1998-10-01), None
patent: WO 98/43960 (1998-10-01), None
patent: 99/61590 (1999-12-01), None
Want, Bioorg & Med Chem Lett, vol. 10, pp. 2477-2480, 2000.
Bridges et al., Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor, J. Med. Chem. 39:267-276 (1996).
Burke, T.R., “Protein-tyrosine kinase inhibitors,” Drugs of the Future 17:119 (1992).
Chang et al., Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents, J. Nat. Prod. 55:1529-1560 (1992).
Dolle et al., 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase, J. Med. Chem. 37(17):2627-2629 (1994).
Du et al., Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD, Am. J. Physiol. 269(2 Pt 1):487-495 (1995).
Fry et al., A specific inhibitor of the epidermal growth factor receptor tyrosine kinase, Science 19:265(5175):1093-1095 (1994).
Gattone et al., Epidermal growth factor ameliorates autosomal recessive polycystic kidney disease in mice, Dev. Biol 169(2):504-510 (1995).
Gazit et al., Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins, J. Med. Chem., 39(11):2170-2177 (1996).
Ife et al., Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-substituted-4-(phenylamino)quinolines, J. Med. Chem. 35(18):3413-3422 (1992).
Maguire et al., A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives, J. Med. Chem. 37:2129-2137 (1994).
Nauta et al., Biliary epithelial cells from mice with congenital polycystic kidney disease are hyperresponsive to epidermal growth factor, Pediatr. Res. 37(6):755-763 (1995).
Wilson et al., Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease, Eur. J. Cell Biol. 61(1):131-138 (1993).
Chang, C.J. et al.,J. Nat. Prod.,55, 1529 (1992).
Du J. et al.,Am. J. Physiol.,269 (2 Pt 1), 487 (1995).
Nauta J. et al.,Pediatric Research,37(6), 755 (1995).
Gattone, V.H. et al.,Developmental Biology,169(2), 504 (1995).
Wilson, P.D. et al.,Eur. J. Cell. Biol.,61(1), 131 (1993).
Ife, R.J. et al.,J. Med. Chem.,35(18), 3413 (1992).
Gazit, A. et al.,J. Med. Chem.,35(11), 2170 (1996).
Dolle, R.E. et al.,J. Med. Chem.,372, 2627, (1994).
Maguire, M.P. et al.,J. Med. Chem.,37, 2129 (1994).
Fry, D.W. et al.,Science,265, 1093 (1994).
Rewcastle, A.J. et al.,J. Med. Chem.,39, 267, (1996).
Bridges, A.J. et al.,J. Med. Chem.,39, 267 (1996).
Berger Dan M.
Floyd, Jr. Middleton B.
Frost Philip
Hamann Philip R.
Tsou Hwei-Ru
Prodnuk Stephen D.
Rubin David
Seaman D. Margaret
Tidwell Jeffrey H.
Wyeth Holdings Corporation
LandOfFree
Substituted 3-cyanoquinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 3-cyanoquinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 3-cyanoquinolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648097